Common variable immunodeficiency (CVID) is a rare condition that affects women of childbearing age with important implications in pregnancy. It is characterised by low immunoglobulins (Igs), poor antibody response and a susceptibility to recurrent infections. The cornerstone of management of CVID is Ig replacement. As the transfer of IgG across the placenta in the third trimester of pregnancy is necessary for protection of the infant in the first months of life, failure to recognise this condition and treat it appropriately can have adverse consequences for the neonate, as well as the mother. Here we describe the complex perinatal medical management of a 34-year-old woman who was diagnosed with CVID in the 26th week of pregnancy.
Introduction
Common variable immunodeficiency (CVID) is a rare condition (estimated prevalence 1:25 000 to 1:50 000) characterised by low levels of immunoglobulin (Ig) G, IgA and/or IgM and poor antibody production. 1 It is frequently associated with recurrent infections, primarily of the upper and lower respiratory tract. A proportion of patients with CVID (8 to 22%) show a variation of the disease, which is associated with the development of granulomas in many tissues and splenomegaly. 2 Patients with the granulomatous form of CVID are particularly susceptible to autoimmune disorders such as idiopathic thrombocytopenia, autoimmune haemolytic anaemia and autoimmune neutropenia. 1, 2 In a minority of pedigrees, CVID shows Mendelian patterns of inheritance, but most cases are sporadic.
Most subjects diagnosed with CVID are adults between the ages of 20 and 40 years, and the average time between the onset of significant symptoms and diagnosis is 6 years. 1, 3 Therefore, the condition may be undiagnosed and untreated in women of childbearing age. The cornerstone of treatment for symptomatic immunodeficiency in CVID is regular Ig replacement. In pregnancy, transport of IgG from the mother to the fetus is important for the protection of the infant in the first months of life, so the under-recognition of CVID in pregnant women is of particular importance, as there may be consequences for the neonate. 4 There are reports in the literature, which describe the management of Ig replacement by the intravenous and subcutaneous routes in pregnant women with CVID, and these have been summarised quite recently. 5 However, we are not aware of any previous cases where the diagnosis was made during pregnancy. In addition to receiving a new diagnosis of CVID, our patient experienced a number of other complications in the perinatal period, the management of which required the close cooperation of several medical specialities. We would like to report our experience of managing this complex case to raise awareness of CVID and its treatment.
Case
A 34-year-old women, in the 24th week of her second pregnancy, presented to her local Emergency Department complaining of a swollen left calf, where she was diagnosed with cellulitis and a concomitant femoral deep vein thrombosis. She was transferred to our trust for further investigation and management when she was found to be neutropenic.
Her first pregnancy 4 years before had been uncomplicated. As a child, she had required regular courses of antibiotics from her general practitioner for respiratory tract infections. Six years previously, she had developed a swelling on her left calf, and skin and bone marrow biopsy had shown the presence of granulomas. She had initially been treated for tuberculosis before the diagnosis was revised to sarcoidosis, for which she was still taking 5 mg of prednisolone daily. There was no noteworthy family history. Significant findings on examination were that she had scattered dusky erythematous macules and papules on her arms, legs and face (see Figure 1) ; there was no lymphadenopathy and the tip of her spleen was palpable. Initial investigations showed her to have neutropenia, lymphopenia, low Igs and a low antibody response to tetanus vaccination (see Table 1 ). During her admission, she showed spiked fevers, and Pseudomonas was isolated from blood and sputum cultures on a septic screen.
The history of recurrent infections, low Igs and poor vaccine response was consistent with a diagnosis of CVID, which in the context of a history of granulomatous skin lesions suggested granulomatous form of CVID with associated autoimmune cytopenias. Her sepsis was treated with intravenous (IV) antibiotics and her deep vein thrombosis was managed with subcutaneous low-molecular weight heparin. The prednisolone dose was increased to 30 mg daily to treat the cytopenias and IVIg replacement was commenced (see Figure 2) . A plan for a normal vaginal delivery at term was made, but at 35/40, the patient developed pruritus and was found to have deranged liver function tests and elevated bile acids. Obstetric cholestasis was suspected, and at 37 weeks, arrangements were made to induce delivery. We administered her last Ig infusion 3 days before delivery and, 2 days before, withheld her low-molecular weight heparin. However, an emergency caesaerean section became necessary on the planned day of delivery, because of fetal distress secondary to placental abruption. Post-operatively, the patient became tachycardic and hypotensive, and her haemoglobin dropped. She underwent a further laporotomy 3 days after delivery, during which 1000 ml of intraperitoneal blood was evacuated and a uterine artery embolisation was performed. The patient made a full recovery with normalisation of her liver function tests 3 months after delivery. However, she continued to complain of pruritus and of new lesions arising on her face. A dermatological review was requested and a skin biopsy of the lesions confirmed granulomatous involvement of her skin (see Figure 1 ). She continues to receive IVIg replacement every 3 weeks. Her son was born healthy and has not required any medical input. Discussion CVID is a rare and clinically heterogeneous condition that is frequently undiagnosed for several years from the onset of symptoms. 1 The granulomatous changes seen in patients with granulomatous form of CVID can be identified years before the hypoglobulinaemia is recognised and, as with our patient, many are inappropriately treated for sarcoidosis. Granulomas most commonly affect the lungs, but they have also been reported in the liver, spleen, kidney, brain, skin and bone marrow. 2 In this case, granulomatous involvement of the liver could have been an alternative explanation for the deranged liver function tests arising in the 35th week of pregnancy. However, there was no evidence of liver granulomas on a CT performed to investigate her postoperative bleeding, and normalisation of her liver function tests after delivery would further support the diagnosis of obstetric cholestasis.
The primary treatment of CVID is Ig replacement using antibodies isolated from healthy donors. Commercial preparations of Ig contain IgG, but negligible amounts of IgA and IgM. For primary antibody deficiencies such as CVID, Ig is administered at 400 to 600 mg kg À1 per month, every 3 to 4 weeks, to achieve a trough IgG level of at least 6 g l À1 , although higher doses can be necessary to prevent infection in some patients. In stable patients receiving a new diagnosis of CVID, the initiation of treatment may be delayed to formally test vaccination response. However, the maintenance of stable, high maternal IgG levels are thought to be necessary for the efficient placental transport of IgG, which crosses the placenta with increasing efficiency after 30 weeks. 4, 5 We were therefore keen to establish this patient on Ig quickly. Adverse reactions related to IVIg treatment are usually minor, such as headache, chills and myalgia, and are easily managed. However, IVIg therapy causes an increase in serum viscosity and has been associated with an increased risk of thromboembolism. 6 As our patient had presented with a deep vein thrombosis, we considered her at an increased risk of this complication and started her on the minimum dose. Furthermore, we planned to administer her final infusion at least 3 days before delivery. The post-operative bleeding and resultant fluid resuscitation was associated with a sharp drop in her IgG level, which we managed with a top-up IVIg infusion (see Figure 2) . The aetiology of the pancytopenia noted at presentation was probably multifactorial, but was likely, at least in part, to be driven by autoimmune mechanisms, and it partially responded to the increased dose of prednisolone and treatment of her sepsis (see Table 1 ).
In conclusion, although CVID is rare, it is important that those involved in perinatal care are aware of this disorder and its management, because it can be undiagnosed in women of childbearing age. Failure to treat it appropriately is potentially deleterious to the health of the neonate. 
